Stay updated on Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Sign up to get notified when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.

Latest updates to the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page
- Check3 days agoChange DetectedRevision history updated to include v3.5.0 and remove v3.4.3. This appears to be a UI/backend update with no changes to study data or functionality.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedA new revision entry (v3.4.3) was added and the previous revision (v3.4.2) was removed in the study record history.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedA new revision entry (v3.4.2) was added and an older revision (v3.4.1) was removed. The latest version also includes the 'Study Status' section in the history view.SummaryDifference0.3%

- Check47 days agoChange DetectedThe history shows a new revision entry for v3.4.1 and the deletion of the previous revision v3.4.0. It reflects an administrative update to the page's revision history.SummaryDifference0.1%

- Check54 days agoChange DetectedThe history page adds a glossary toggle and a legend for color-coded changes (green for additions, red for deletions) in the study record view, and updates the footer to Revision: v3.4.0 with minor text tweaks such as capitalization changes for 'No FEAR Act'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check69 days agoChange DetectedMinor platform version update reflected in the Record History page: Revision v3.3.4 added and Revision v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 1/2 Pacritinib & Sirolimus for GVHD Prevention Clinical Trial page.